Your browser doesn't support javascript.
loading
A novel approach for BCR-ABL1 standardization to improve International Scale estimation.
Maes, B; Bakkus, M; Boeckx, N; Boone, E; Cauwelier, B; Denys, B; De Schouwer, P; Devos, T; El Housni, H; Hillen, F; Jacobs, K; Lambert, F; Louagie, H; Maes, M-B; Meeus, P; Moreau, E; Nollet, F; Peeters, K; Saussoy, P; Van Lint, P; Vaerman, J-L; Vaeyens, F; Vandepoele, K; Vannuffel, P; Ver Elst, K; Vermeulen, K; Bruyndonckx, R.
Afiliação
  • Maes B; Laboratory for Molecular Diagnostics, Jessa Hospital, Hasselt, Belgium.
  • Bakkus M; Laboratory of Haematology, University Hospital Brussels, Brussels, Belgium.
  • Boeckx N; Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
  • Boone E; Laboratory for Molecular Diagnostics, AZ Delta, Roeselare, Belgium.
  • Cauwelier B; Department of Laboratory Medicine, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.
  • Denys B; Laboratory for Molecular Diagnostics - Haematology, University Hospital Gent, Gent, Belgium.
  • De Schouwer P; Laboratory of Haematology, ZNA Antwerp, Antwerp, Belgium.
  • Devos T; Department of Haematology, University Hospitals, Leuven, Belgium.
  • El Housni H; CUB Erasme, Brussels, Belgium.
  • Hillen F; Laboratory for Molecular Diagnostics, Jessa Hospital, Hasselt, Belgium.
  • Jacobs K; Clinical Laboratory, AZ Sint-Lucas, Gent, Belgium.
  • Lambert F; Laboratory for Molecular Diagnostics, Haemato-Oncology Unit, University Hospital Liege, Liege, Belgium.
  • Louagie H; Clinical Laboratory, AZ Sint-Lucas, Gent, Belgium.
  • Maes MB; Laboratory of Haematology, University Hospital of Antwerp, Antwerp, Belgium.
  • Meeus P; Laboratory for Molecular Diagnostics, OLV Ziekenhuis Aalst, Aalst, Belgium.
  • Moreau E; Laboratory for Molecular Diagnostics, AZ Delta, Roeselare, Belgium.
  • Nollet F; Department of Laboratory Medicine, AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium.
  • Peeters K; Novartis Pharma, Vilvoorde, Belgium.
  • Saussoy P; Laboratoire de biologie moléculaire, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
  • Van Lint P; Department of Molecular Diagnostics, GZA St-Augustinus, Wilrijk, Belgium.
  • Vaerman JL; Laboratoire de biologie moléculaire, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
  • Vaeyens F; Laboratory for Molecular Diagnostics, OLV Ziekenhuis Aalst, Aalst, Belgium.
  • Vandepoele K; Laboratory for Molecular Diagnostics - Haematology, University Hospital Gent, Gent, Belgium.
  • Vannuffel P; Institut de Pathologie et de Génétique, Gosselies, Belgium.
  • Ver Elst K; Department of Molecular Diagnostics, GZA St-Augustinus, Wilrijk, Belgium.
  • Vermeulen K; Laboratory of Haematology, University Hospital of Antwerp, Antwerp, Belgium.
  • Bruyndonckx R; Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BIOSTAT), University of Hasselt, Diepenbeek, Belgium.
Int J Lab Hematol ; 38(6): 674-684, 2016 Dec.
Article em En | MEDLINE | ID: mdl-27460189
INTRODUCTION: Standardization of BCR-ABL1 messenger RNA quantification by real-time PCR on the International Scale (IS) is critical for monitoring therapy response in chronic myelogenous leukaemia. Since 2006, BCR-ABL1 IS standardization is propagated along reference laboratories by calculating a laboratory-specific conversion factor (CF), co-ordinated in Europe through the European Treatment and Outcome Study project. Although this process has proven successful to some extent, it has not been achievable for all laboratories due to the complexity of the process and the stringent requirements in terms of numbers of samples to be exchanged. In addition, several BCR-ABL1 IS quantification methods and secondary reference materials became commercially available. However, it was observed that different IS methods generate consistently different results. METHODS: To overcome these difficulties, we have developed an alternative and simple approach of CF calculation, based on the retrospective analysis of existing external quality assessment (EQA) data. Our approach does not depend on the exchange of samples and is solely based on the mathematical CF calculation using EQA results. RESULTS AND CONCLUSION: We have demonstrated by thorough statistical validation that this approach performs well in converting BCR-ABL1 measurements to improve IS estimation. In expectation of a true golden standard method for BCR-ABL1 IS quantification, the proposed method is a valuable alternative.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Mensageiro / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: RNA Mensageiro / Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl Idioma: En Ano de publicação: 2016 Tipo de documento: Article